The committee approved:
a number of recommendations resulting from a review of the Fund's Strathclyde Direct Investment Portfolio
a new investment of £15m from the Direct Investment Portfolio into Epidarex Capital III LP, A Scottish life sciences venture capital fund
the conclusions of a review of the Strathclyde (No.3) Pension Fund and
a final response to the current review of the structure of the Local Government Pension Scheme in Scotland.
The committee also considered a number of administration, audit, finance and investment reports.
The Fund's total return for Q3 2018 (to end September) was +2.6%.